In 2023, the Swiss Biotech Association reported that the life sciences sector—pharmaceuticals, vitamins and diagnostics—became the country’s largest export industry. Swiss biotech revenues ...

Japan-based Taiho Pharmaceuticals on Monday said it will acquire Switzerland’s Araris Biotech and its antibody-drug conjugate ...

Amid Trump’s dismantling of DEI, Roche wiped diversity targets from the website of its US subsidiary, Genentech, in mid-February. Basel-based competitor Novartis also said this week it was getting rid ...

Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC) linker platform.

If completed, it is thought that this would be the first IPO by a Swiss biotech since Polyphor – another antibiotic developer now called Spexis – went public in 2018. While there has been a ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a ...

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics.

Emergent has entered a strategic financial investment agreement with Swiss Rockets to support the latter’s biotech portfolio.

Japan’s Taiho Pharmaceutical announced the purchase of Araris Biotech of Switzerland for up to $1.14bn. The agreement involves an upfront payment of $400mn plus a potential maximum of $740mn in ...